Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Accumulated Depreciation (2016 - 2025)

Rocket Pharmaceuticals' Accumulated Depreciation history spans 9 years, with the latest figure at $27.4 million for Q3 2025.

  • For Q3 2025, Accumulated Depreciation rose 41.24% year-over-year to $27.4 million; the TTM value through Sep 2025 reached $27.4 million, up 41.24%, while the annual FY2024 figure was $21.3 million, 51.46% up from the prior year.
  • Accumulated Depreciation for Q3 2025 was $27.4 million at Rocket Pharmaceuticals, up from $23.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $27.4 million in Q3 2025 and bottomed at $5.2 million in Q4 2021.
  • The 5-year median for Accumulated Depreciation is $14.0 million (2023), against an average of $14.4 million.
  • The largest annual shift saw Accumulated Depreciation skyrocketed 74.1% in 2022 before it surged 41.24% in 2025.
  • A 5-year view of Accumulated Depreciation shows it stood at $5.2 million in 2021, then surged by 74.1% to $9.1 million in 2022, then skyrocketed by 54.32% to $14.0 million in 2023, then surged by 51.46% to $21.3 million in 2024, then increased by 29.13% to $27.4 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Accumulated Depreciation are $27.4 million (Q3 2025), $23.7 million (Q1 2025), and $21.3 million (Q4 2024).